Discovery of potent and selective inhibitors of 11beta-HSD1 for the treatment of metabolic syndrome.
High throughput screening efforts have identified a novel class of dichloroaniline amide 11beta-HSD1 inhibitors. SAR studies initiated from dichloroaniline 4 focused on retaining the potency and selectivity profile of the lead.